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Overview of data from the control cohort
The data on incidence of clinical malaria in the control cohort provides valuable information on the intensity and seasonality of malaria transmission in each trial site. Figure S1 shows the recorded cases of malaria broken down by time and trial site for the according-to-protocol (ATP) population over the period from month 2•5 to study end.
There was a large degree of variation in transmission intensity and seasonality between sites. The primary case definition of an episode of clinical malaria is used: illness in a child brought to a study facility with a measured temperature of ≥37•5°C or reported fever within the last 24 hours and P. falciparum asexual parasitaemia at a density of >5000 parasites per cubic millimetre. This parasite threshold is within a sufficient range to ensure optimal statistical power in studies of the efficacy of pre-erythrocytic vaccines 1 . Figure S1 : Total numbers of cases of clinical malaria (primary case definition) in the control arm for each of the 11 trial sites.
In addition to heterogeneity between sites, there was substantial heterogeneity within sites in the incidence of clinical of malaria, with some children experiencing a large number of episodes and many children not experiencing any episodes over the duration of the trial. The distribution of episodes of clinical malaria within each trial site is shown for the 6-12 week age category ( Figure S2 ) and for the 5-17 month age category ( Figure S3 ). As illustrated above, the incidence of clinical malaria in the control cohort depends on site-level transmission intensity and seasonality. The incidence of clinical malaria also depends on age. This is due to the acquisition of clinical immunity over time as children are exposed to malaria 2, 3 . In addition, as children grow older they are exposed to a greater number of mosquito bites due to their increased body size 4, 5 . Figure S4 shows the ageincidence curves for each trial site based on reported cases of malaria (primary case definition) in the control cohort. Figure S4 : Age-incidence curves of clinical malaria (primary definition) in the control cohort for the according-to-protocol (ATP) population. Clinical incidence was calculated as the number of cases in 3 month age bins divided by the time at risk in each bin. Edge effects due to small sample sizes are apparent in some cases. In sites with higher transmission intensity an increase in cases is apparent over the first two years. There is evidence of decreasing transmission intensity in two sites (Bagamoyo and Lilongwe).
Determinants of immunogenicity 2.1. Overview of immunogenicity data
The immunogenicity of RTS,S/AS01 was evaluated via its capacity to induce anti-CS antibody titres following a primary vaccination schedule (CS peak ) or following a booster dose (CS boost ). The magnitude of anti-hepatitis B (HBs) antibody titres induced following vaccination with RTS,S/AS01 (HBs peak ) also provides valuable information on immunogenicity. Phase 2 trials of the RTS,S/AS01 and RTS,S/AS02 vaccines have demonstrated that peak anti-CS antibody titres following a primary schedule of RTS,S depend on a number of covariates such as age and baseline antibody titres 6 . Notable findings from phase 2 trials included:
 Children (aged > 3 months and < 5 years) had higher antibody responses than infants (aged < 3 months) 7, 8 .  RTS,S/AS01 induced higher antibody responses than RTS,S/AS02 9, 10 .  Receiving 3 doses of RTS,S induced higher antibody responses than 2 doses.
 In infants, high baseline anti-CS antibody titres were associated with lower peak anti-CS antibody titres postvaccination. This may be attributable to maternally acquired antibodies inhibiting the vaccine-induced antibody response 11 .
 In children, baseline anti-HBs antibody titres (most likely due to prior Hepatitis B vaccination) were associated with higher peak anti-CS antibody titres 12 .
Data from the phase 3 trials of the RTS,S/AS01 vaccine were analysed to investigate the determinants of immunogenicity following primary vaccination with or without a booster dose. Anti-CS antibodies were measured by ELISA in the first 200 participants in each age category at each study site at enrolment and 1 month after the third dose of vaccine. This assay was based on the binding of serum antibodies to R32LR, a recombinant protein composed of the repeat region of P. falciparum CS. The threshold for a positive titer was 0.5 EU/ml 13 . Figure S5 shows the dependence on age at first dose of anti-CS antibody titres at baseline (CS base ), following primary vaccination (CS peak ) and following a booster dose (CS boost ). Figure S6 and Figure S7 show the associations between anti-CS and anti-HBs antibody titres at baseline, following primary vaccination and following a booster dose in the 6-12 week and 5-17 month age categories respectively. Dependence on age at first dose of baseline anti-CS antibody titres (CS base ), anti-CS antibody titres following a primary schedule of RTS,S/AS01 (CS peak ) and anti-CS antibody titres following a booster dose (CS boost ). The black lines show the association between antibody titres and age predicted by linear regression models. The dashed grey lines depict the variation in the data. 
Statistical analysis of immunogenicity data
The immunogenicity of RTS,S/AS01 (as measured by anti-CS antibody titres following primary vaccination or a booster dose) was analysed to investigate the dependence on a number of covariates. Covariates considered included:
 age category (6-12 weeks or 5-17 months)  age at first dose (in months)
 HIV status (confirmed positive)  gender  site-level transmission intensity (based on incidence of clinical malaria in the control cohort)  pre-term delivery  very low weight-for-age z-score  previous cases of malaria (analysis of booster data only)  CS base : anti-CS antibody titre at screening  HBs base : anti-HBs antibody titre at screening  CS peak : peak anti-CS antibody titre (analysis of booster data only)
The data were analysed using linear regression models with trial site included as independent random effects. Table   S1 shows the results of the linear regression models with all covariates included. Table 2 of the main manuscript shows the results of a linear regression model with some of the non-significant covariates removed. A number of statistically significant associations are evident for peak anti-CS antibody titres following a primary schedule of RTS,S/AS01:  Children in the 5-17 month age category had higher antibody responses than infants in the 6-12 week age category.
 Within the 5-17 month age category age was negatively associated with anti-CS antibody response.
 HIV infection was associated with significantly lower anti-CS antibody responses.
 Pre-term delivery or very low weight-for-age z-scores were not associated with impaired anti-CS antibody responses.
 In the 6-12 week age category, pre-vaccination anti-CS antibody titres were associated with lower peak anti-CS antibody titres. This finding is consistent with the hypothesis that maternal antibodies reduce the immunogenicity of RTS,S 11 .
 No statistically significant associations were detected between pre-vaccination anti-HBs antibodies and peak anti-CS antibody titres. This finding is in contrast to results from phase 2 trials which found baseline anti-HBs titres to be positively associated with RTS,S immunogenicity 12 . However, these findings are consistent with the hypothesis that it is prior hepatitis B vaccination status and not the magnitude of the anti-HBs antibody titre that affects RTS,S immunogenicity. Note that all children and infants in the phase 3 trial of RTS,S/AS01 received prior anti-hepatitis B vaccination.
The data from individuals in the R3R cohort were analysed to investigate the determinants of immunogenicity following a booster dose of RTS,S/AS01 (Table 2 and Table S1 ). A number of statistically significant associations are evident:
 The most significant predictor of boosted anti-CS antibody titre is peak anti-CS antibody titre.
 There were no statistically significant associations between age at first dose and boosted anti-CS antibody titres at the 5% significance level. At the 10% level, increased age was associated with lower boosted anti-CS antibody titre in the 5 to 17 month cohort. Increased age at first dose was associated with higher boosted anti-CS antibody titre in the 6 to 12 week cohort.
 There was no statistically significant association between boosted anti-CS antibody titres and recent malaria exposure (as measured by the number of cases of clinical malaria between dose 3 and the booster dose). A negative association may have indicated immunosuppression by malaria infection. Table S1 : Determinants of immunogenicity of RTS,S/AS01 including non-significant covariates.
Estimates from linear regression analyses of the impact of covariates on peak anti-CS antibody titre following primary vaccination of RTS,S/AS01 ( log 10 ( CS peak / (EU/mL) ) ) or following a booster dose ( log 10 ( CS boost / (EU/mL) ) ). The baseline is taken to be vaccination of a child in the 5-17 month age category. Trial site was included in the regression models as a random effect. Transmission intensity was accounted for using the incidence of cases of clinical malaria in the control cohort of the 6-12 week age category ( Table 1 ). The number of cases of clinical malaria between dose 3 and the booster dose was counted as cases before booster. ¶ indicates the change associated with a one month change in age. † indicates the change associated with a 10-fold change in titre. The effect of RTS,S/AS01 on anti-hepatitis B antibody titres following vaccination was also analysed using linear regression models (Table S2) . RTS,S/AS01 was more immunogenic in the 5-17 month age category ( GMT = 83472 (95% range: 5203, 681620) EU/mL ) compared to the 6-12 week age category ( GMT = 13474 (95% range: 1014, 98408) EU/mL ). Estimates from linear regression analyses of the impact of covariates on peak anti-HBs antibody titre following primary vaccination of RTS,S/AS01 ( log 10 ( HBs peak / (EU/mL) ) ). The baseline is taken to be vaccination of a child in the 5-17 month age category. Trial site was included in the regression models as a random effect. Transmission intensity was accounted for using the incidence of cases of clinical malaria in the control cohort of the 6-12 week age category (Table 1) . ¶ indicates the change associated with a one month change in age. † indicates the change associated with a 10-fold change in titre. The variation in peak and boosted anti-CS and anti-HBs antibody titres between trial sites is only partially explained by the covariates tested above, and must instead be accounted for through the site-specific random effects. It is possible that this variation may be explained by a multitude of other unmeasured factors such as host-specific genetic variation, nutrition, or immunosuppression due to helminth infection 14 .
Anti-CS antibody dynamics

Antibody dynamics model
The patterns of waning of anti-CS antibody titres following RTS,S/AS01 vaccination without (R3C) and with (R3R) a booster dose at 18 months are shown in Figure S8 . Also shown is the anti-CS antibody titres over time for members of the control cohort (C3C). Anti-CS GMTs in the control cohort are orders of magnitude lower than anti-CS GMTs in both of the vaccine cohorts throughout follow-up. Following vaccination with a primary schedule of RTS,S/AS01, anti-CS antibody titres are assumed to increase to CS peak and then wane over time t according to a bi-phasic exponential model as follows: For a participant with serological data, CS peak and CS boost can be measured directly from the data. It is also possible to obtain estimates of CS peak and CS boost using the regression models from section 2 and data on covariates such as age and pre-vaccination antibody titres. However, we prefer to directly use the measured antibody titres to avoid the uncertainty in the regression models from affecting the antibody dynamics models. 
Fitting the model to data
The model was fitted to longitudinal antibody titre measurements from vaccinated participants in each study site.
Mixed effects methods were used to capture the natural variation in antibody dynamics between individual participants, whilst estimating the average value and variance of the immune parameters across the entire cohort of children 15 . The models were fitted in a Bayesian framework using Markov Chain Monte Carlo (MCMC) methods.
Mixed effects methods allow local parameters to be estimated for each child individually, with these local (or mixed effects) parameters being drawn from global distributions 
Model likelihood
For participant n we have data on observed antibody titres
to be the vector of data for participant n. For participant n, the four parameters 
Mixed effects likelihood
There are four mixed effects parameters to be estimated:
As the proportion of the antibody response that is short-lived must be bounded by 0 and 1, the local parameters 
Total model likelihood
to be the vector of data for all N participants. We denote
..,
to be the combined vector of global parameters and local parameters to be estimated. The total likelihood is obtained by multiplying the likelihood for each child
Markov Chain Monte Carlo parameter update
The model was fitted to the data using Markov Chain Monte Carlo (MCMC) methods. Parameters were updated at each MCMC iteration using a random walk Metropolis-Hastings algorithm with two update stages illustrated below.
A ′ indicates an attempted update.
Local parameter update. For each participant n:
 Update local parameters:
 Accept the parameter update with probability
Global parameter update.
 Update global parameters:
and the updated prior probability density   P    Accept the parameter update with probability
All updates were attempted with Normal proposal distributions. The MCMC algorithm was implemented in C++.
The variances of the proposal distributions were first estimated by performing 1 million MCMC iterations to estimate the variance of the posterior distributions. 20 million MCMC iterations were computed with calibration of acceptance rates using a Robbins-Munro algorithm 17 . All Markov chains were visually examined for appropriate mixing and convergence. Such large numbers of iterations were needed because of the large number of parameters to be estimated. Convergence was formally tested for using the Gelman-Rubin statistic 18 , which was found to be less than 1.05 in all cases suggesting adequate convergence. The effective number of iterations was calculated using the effectiveSize routine in the R library coda 19 and the effective size was checked to be > 1,000 for the global parameters. The MCMC fitting process was repeated multiple times to ensure consistent results and test for lack of convergence.
The model was fitted to data from both cohorts and the parameter estimates are presented in Table S3 . Prior distributions for the global parameters were derived from a study of the Phase 2 data 6 . Note that very informative priors were selected for the half-life of the short-lived component of the antibody response, due to the lack of measurements between the peak antibody response at month 3, and the next measurement at month 20 before the booster dose. Thus, the Phase 3 data has very little statistical power to estimate the half-life of the short-lived component of the antibody response. Table S3 : Estimates of parameters describing the dynamics of RTS,S-induced anti-CS antibodies using mixed effects models. Priors and posteriors are presented as median and 95% credible intervals. U denotes a uniform distribution. Gamma priors were assumed for d s and d l . Beta priors were assumed for ρ peak and ρ boost . Note that the mean and median of a distribution are not necessarily equal. 
Alternative models of antibody dynamics
The mathematical model of antibody dynamics described above assumes that following vaccination, the decay of anti-CS antibody titres over time can be described by a bi-phasic exponential process. This corresponds to an immunological model where antibodies are generated by two populations of antibody secreting plasma B cells: one short-lived and one long-lived 20 . This model is equivalent to the plasma cell driven kinetic (PCDK) model described by Andraud et al 21 . The decay of vaccine-induced antibody responses has also been described using a power law model 22 .
Here we describe details of two alternative models of antibody dynamics following vaccination: a single exponential decay model; and a power law decay model.
Under a single exponential decay model, following primary vaccination with RTS,S, it is assumed that anti-CS antibody titres decay exponentially with half-life d peak as follows:
where r peak = log(2)/d peak . Following a booster dose at time t boost it is assumed that anti-CS antibody titres are boosted to CS boost and decay exponentially with half-life d boost as follows:
Under a conventional power law decay model as described by Fraser et al 22 , following primary vaccination with RTS,S it is assumed that anti-CS antibody titres are described by:
where k PL is a shape parameter to be estimated. In particular, k PL is the shape parameter of a Gamma distribution.
The model assumes that antibodies are generated by antibody secreting cells which have half-lives distributed according to a Gamma distribution. Following a booster dose at time t boost it is assumed that anti-CS antibody titres are boosted to CS boost and decay as follows:
Both models were fitted to the same data using the same methods as for the bi-phasic exponential described above. Table S4 shows the estimated parameters for the single phase exponential model. Table S5 shows the estimated parameters for the conventional power law decay model. Figure S11 shows a comparison between the single exponential model and the data. Visual examination of the model fits in Figure S11 is sufficient to demonstrate that the single exponential model does not replicate the patterns of decay of antibody response observed in the data. 
Association between anti-CS antibodies and efficacy
Vaccine efficacy profiles
Measurement of the effectiveness of malaria vaccines in Phase 2 and Phase 3 trials has focussed on statistical estimation of point estimates of vaccine efficacy over fixed time periods (e.g. 0-9 months, 0-2 years) [23] [24] [25] [26] . Although adequately powered to accurately assess efficacy, most conventional statistical methods are not designed to robustly estimate the duration of protection 27 . Here we describe statistical methods for estimating both efficacy and duration of protection. We define the vaccine efficacy profile to be the combination of initial efficacy and the pattern of decay over time. A vaccine efficacy profile can be considered for various endpoints, in particular P.
falciparum infection and episodes of clinical malaria. Three different vaccine efficacy profiles are considered here.
Exponential profile
Vaccine efficacy is assumed to begin at V 0 and wane exponentially over time with rate 0 0 
After a booster dose at time t boost efficacy is boosted to V boost . The rates of decay of the short-lived and long-lived components of vaccine efficacy may change after the booster dose, but we assume they remain the same. However, we assume that the proportion of efficacy that is short-lived may change to ρ bp,boost after the booster dose. 
Antibody profile
We consider the special case where the waning of efficacy against infection over time can be determined by the waning of vaccine-induced antibody responses. In particular, we assume that following vaccination with RTS,S/AS01 the change in anti-CS antibody titres can be described by equations (S1) and (S2). The model-predicted antibody titre at time t can be used to predict vaccine efficacy against P. falciparum infection via a dose-response curve defined as follows:
where V max , α and β are parameters to be estimated. Equation (S12) is a functional formal regularly used in pharmacokinetics/pharamacodynamics for modelling dose-relationships Figure S12: Examples of dose-response relationships described by equation (S14). It is assumed that β = 50 and V max = 90%.
Seasonality in exposure
There is substantial seasonal variation in the incidence of clinical malaria in the control cohort in all sites ( Figure S1 ).
The following functional form has been used by Griffin et al 29 to capture patterns of seasonal malaria transmission with a single peak: Here we extend this functional form to also account for geographical regions with two distinct peaks in malaria transmission (e.g. parts of east Africa with two rainy seasons). 
. Figure S13 shows the best fit of the double-peak seasonality profile in equation (S16) to data on episodes of clinical malaria from the control cohort for each of the 11 trial sites.
The seasonality parameters for each site are provided in Table S6 . 
Models for the incidence of clinical malaria
The pattern of incidence of symptomatic episodes of clinical malaria will depend on exposure to infectious mosquito bites and age. Such patterns can be described by age-incidence curves. Age-incidence curves can be estimated statistically from epidemiological data on the incidence of clinical malaria 2, 31 . Alternatively they can be estimated using mathematical models that incorporate biological insights into the acquisition of clinical immunity 29, 32, 33 . The advantage of a statistical age-incidence model is that it allows estimation of clinical incidence in a trial site given an individual's age. However, age-incidence curves do not allow for robust comparisons between sites of differing transmission intensity. Mathematical models accounting for the age and exposure dependent acquisition of clinical immunity allow for estimates of the probability that blood-stage P. falciparum infection will progress to an episode of clinical malaria. Here, we describe the immunity acquisition model used in the main manuscript. In Section 5 we describe an alternative approach using age-incidence curves for the incidence of episodes of clinical malaria 2 .
The immunity acquisition model is based on a previously validated model of malaria transmission dynamics and the age and exposure dependent acquisition of clinical immunity 29, 32 . We assume that each participant n is subjected to a fixed entomological inoculation rate (EIR) depending on their trial site, denoted EIR n . A participant's exposure to infectious bites will depend on their age a. Young children are assumed to receive fewer mosquito bites than adults due to their smaller body sizes and tendency to spend more time indoors at night time 4, 5 . The rate at which a trial participant of age a is exposed to infectious bites is thus dependent on their age and trial site and can be modelled as:
For individuals sleeping under LLINs, the rate of exposure to infectious bites is adjusted by a further factor γ LLIN :
The probability that a bite from an infectious mosquito progresses to blood-stage infection in an unvaccinated participant can be described by the previously described functional form 32 :
where I B (t) is the time-dependent immunity against infection, and b 0 , b 1 , I B0 and κ B are immune parameters defined in Table S7 . The probability of infection per mosquito bite b(t) is assumed to decrease with increasing levels of infection-blocking immunity I B (t), however this is assumed to be independent of RTS,S induced anti-CS antibody titres CS(t). Note that this natural infection-blocking immunity is estimated to have very little effect in these young cohorts 34 and hence is just included here for completeness. The time-dependent hazard of infection on an unvaccinated trial participant at time t after vaccination is then given by:
where S n (t) is the seasonality profile in equation (S16). And the time-dependent hazard of infection on a vaccinated trial participant is
Using a similar functional form we can calculate the probability that an infection leads to an episode of clinical
where I CA (t) is the time-dependent immunity against clinical malaria, I CM (t) the time-dependent maternal immunity against clinical malaria, and φ 0 , φ 1 , I C0 and κ C are immune parameters defined in Table S7 . The time dependent
hazard of an episode of clinical malaria in an unvaccinated trial participant can be modelled as
H t S t a t b t t    
(S23) And the time-dependent hazard of an episode of clinical malaria in a vaccinated trial participant is given by
The rate at which episodes of clinical malaria were detected in trials was adjusted by a further factor r CLIN to account for differences in the definition of a case of clinical malaria between the data used to parameterise the model 32 and the primary case definition in the trial. Thus
The acquisition of immunity against infection ( I B ) and clinical malaria ( I CA ) is described by the following set of differential equations
where u B, d B , u C and d C are immune parameters as defined in Table S7 . Maternal clinical immunity I CM is assumed to be at birth a proportion P M of the acquired immunity of a 20 year old and to decay at rate 1 
Model likelihood for survival analysis
Using the incidence of clinical malaria H(t) from either the age-incidence model or the immunity-acquisition model we can construct a model likelihood using survival analysis methods. We assume that, accounting for seasonality in transmission, EIR remains constant throughout the trial, e.g. there is no decline in transmission over the five years of the trial.
A participant n in a vaccine trial with clinical malaria as an endpoint will be followed up for time T n and experience I n episodes of clinical malaria at times 1 { ,..., } n n n I   . We estimate two sets of parameters -EIR and  where the latter denotes the set of model parameters for vaccine efficacy profiles. The likelihood of these parameters given the data is:
Note that we have incorporated a censoring period after each episode into the likelihood (T cen = 14 days). This accounts for the period of time after an episode of clinical malaria where a participant is under chemoprophylaxis and thus protected from a second episode. In instances where two episodes of clinical are observed within T cen = 14 days of each other in the data, the second episode is censored.
We can incorporate heterogeneity in exposure to infectious bites using a Gamma distribution with shape parameter k so that the mean number of infectious bites per day is EIR n with variance (EIR n ) 2 /k. Heterogeneity in exposure can be accounted for by integrating over x -the range of EIR with mean EIR n and shape parameter k:
where Γ d (x|EIR n ,k) is a Gamma distribution with mean EIR n and shape parameter k defined as follows:
Note that the subscript d denotes the Gamma distribution as opposed to the Gamma function. Equation (S29) can be evaluated numerically using Gaussian quadrature with weights (w j ) and abscissas (x j ) derived from Gauss-Laguerre polynomials. We use 10 abscissas for numerical evaluation. The total likelihood for all N participants with episodes of clinical malaria as an endpoint can be obtained by multiplying each participant's likelihood in equation
In the model likelihood described above episodes of clinical malaria are assumed to be due to variation in expsoure, age, LLIN status, an individual's level of naturally-acquired immunity, and an individual's vaccination status. After accounting for these factors, episodes of clinical malaria within an individual are assumed to be independent.
The model described above was fitted to data using Bayesian MCMC methods. The MCMC algorithm was implemented in C++. All updates were attempted with Normal proposal distributions. All Markov chains were visually examined for appropriate mixing and convergence. The MCMC fitting process was repeated twice to ensure consistent results and test for lack of convergence. Convergence was also formally tested for using the GelmanRubin statistic 18 . Posterior median parameter estimates with 95% credible intervals are presented in Table S8 for several vaccine efficacy profiles. 
Additional results
Here we compare the vaccine efficacy profiles for infection described in Section 4.1. In addition we consider a scenario where the antibody dose-response relationship in equation (S12) has different scale parameters for infants and children. The parameter estimates for each of the tested vaccine efficacy profiles are presented in Table S7 .
The model with a separate dose-response curves for each age category (antibody model: 2β) was implemented by allowing a separate dose-response scale parameter for each age category: β 6w12w and β 5m17m . This model produced very similar dose-response curves to the antibody model with a single dose-response curve ( Figure S14 ). In particular, the estimated curves from antibody model: 2β fell within the 95% credible intervals of the dose-response curve from the antibody model. Table S7 ). The shaded grey region denotes the 95% credible interval for the estimated dose-response curve for the antibody model fitted to data from all participants Given the efficacy profile for infection the efficacy profile for clinical malaria can also be predicted, however it will be dependent on transmission intensity. Figures S16 show the estimated efficacy against clinical malaria at a range of transmission intensities (EIR = 1, 5, 10, 30, 50) using the antibody model. Efficacy against clinical malaria decays more rapidly than efficacy against infection (especially in high transmission settings) due to higher levels of natural immunity in the control cohort than the vaccine cohort. In high transmission settings incidence of clinical malaria in the vaccine cohort may be greater than incidence in the control cohort after 3 -4 years leading to negative efficacy. This is due to reduced rates of acquisition of immunity and the shifting of episodes of malaria from younger children to older ones.
Note that at very high transmission intensity, efficacy against clinical malaria is predicted to be negative, i.e. the incidence of clinical malaria is higher in the vaccine cohort than the control cohort at that time. In all cases tested here, the net number of cases averted by vaccination remains positive. Figure S17 and Figure S18 show detailed model validation for Lilongwe and Nanoro, demonstrating how the model recreates seasonality and age-incidence patterns for each of the vaccine cohorts and both age categories. Similar plots are possible for the other nine trial sites.
Additional model validation
Figure S17: Validation of the antibody dynamics model for Lilongwe (a moderate transmission site).
The vaccine efficacy profile for infection is determined by anti-CS antibody titres and the dose-response relationship. The data are shown as cases over calendar time to present seasonal and temporal variation. Age-incidence curves are shown to present variation in incidence of clinical malaria with age. The right-hand column shows estimated efficacy against clinical malaria. Data are presented as point estimates with 95% confidence intervals. The posterior median of the age-incidence model is shown as a smooth line. 6w12w = 6-12 week age category. 5m17m = 5-17 month age category. C3C = control cohort. R3C = primary schedule of RTS,S/AS01 without a booster dose. R3R = primary schedule of RTS,S/AS01 with a booster dose. The vaccine efficacy profile for infection is determined by anti-CS antibody titres and the dose-response relationship. The data are shown as cases over calendar time to present seasonal and temporal variation. Age-incidence curves are shown to present variation in incidence of clinical malaria with age. The right-hand column shows estimated efficacy against clinical malaria. Data are presented as point estimates with 95% confidence intervals. The posterior median of the age-incidence model is shown as a smooth line. 6w12w = 6-12 week age category. 5m17m = 5-17 month age category. C3C = control cohort. R3C = primary schedule of RTS,S/AS01 without a booster dose. R3R = primary schedule of RTS,S/AS01 with a booster dose. Note the mismatch in seasonality patterns in the age-incidence curves for the 6-12 week age category. This is because the serological cohort was a subset of the total cohort. In particular, the first children enrolled were assigned to the serology cohort resulting in a different seasonal profile.
Age-incidence model
The incidence of clinical malaria depends on age and transmission intensity, amongst other factors 2, 31 . Carneiro et al 2 undertook a systematic review of studies of the dependence of clinical incidence on age, and found the ageincidence relationship to be well described by a log-Normal distribution. We fit these age-incidence curves to data on cases of clinical malaria for each trial site, adjusting for seasonality and bed net usage.
An advantage of age-incidence models is that they do not depend on the assumptions inherent in mathematical models of malaria transmission or the acquisition of natural immunity 32, 35, 36 . Statistical age-incidence models can be fitted to data from one trial site at a time. Data from multiple sites with different transmission intensity cannot be combined using this method. Due to variation in transmission intensity, a separate estimate of the vaccine efficacy profile for clinical malaria is estimated for each trial site. A drawback of only being able to analyse data from a single trial site at a time is the limitation on statistical power, particularly in low transmission sites where no clear pattern of vaccine efficacy profile is evident from the data. Notably, we only fitted an exponential vaccine efficacy profile.
The data were not informative enough to justify the additional parameters required for more detailed profiles such as a bi-phasic exponential efficacy profile.
Model description
Following the approach of Carneiro et al 2 we assume that for each trial site, the relationship between age and the incidence of clinical malaria can be described by a log-Normal distribution as follows: 
Results of age-incidence model
The age-incidence model was fitted separately to data from each of the 11 trial sites assuming an exponential vaccine efficacy profile for clinical malaria. The likelihood in equation (S31) was used to describe the fit of the model to the data and the same Bayesian MCMC fitting methods were used. Full posterior parameter estimates are provided in Table S9 . The predicted efficacy profiles for clinical malaria are shown for the 6-12 week age category ( Figure S19 ) and the 5-17 month age category ( Figure S20 ). (Table S6) . Table S9 : MCMC parameter estimates for age-incidence models of clinical malaria 2 fitted to data from one trial site at a time. Half-life is presented in years. Figure S22 and Figure S23 show detailed model validation for Lilongwe and Nanoro, demonstrating how the ageincidence model recreates seasonality and age-incidence patterns for each of the vaccine cohorts and both age categories. Similar plots are possible for the other nine trial sites.
Kilifi
Model validation
Figure S22: Validation of the age-incidence model for Lilongwe (a moderate transmission site).
An exponential vaccine efficacy profile for clinical malaria is assumed. The data are shown as cases over calendar time to present seasonal and temporal variation. Age-incidence curves are shown to present variation in incidence of clinical malaria with age. The right-hand column shows estimated efficacy against clinical malaria. Data are presented as point estimates with 95% confidence intervals. The posterior median of the age-incidence model is shown as a smooth line. 6w12w = 6-12 week age category. 5m17m = 5-17 month age category. C3C = control cohort. R3C = primary schedule of RTS,S/AS01 without a booster dose. R3R = primary schedule of RTS,S/AS01 with a booster dose. Figure S23 : Validation of the age-incidence model for Nanoro (a high transmission site). An exponential vaccine efficacy profile for clinical malaria is assumed. The data are shown as cases over calendar time to present seasonal and temporal variation. Age-incidence curves are shown to present variation in incidence of clinical malaria with age. The right-hand column shows estimated efficacy against clinical malaria. Data are presented as point estimates with 95% confidence intervals. The posterior median of the age-incidence model is shown as a smooth line. 6w12w = 6-12 week age category. 5m17m = 5-17 month age category. C3C = control cohort. R3C = primary schedule of RTS,S/AS01 without a booster dose. R3R = primary schedule of RTS,S/AS01 with a booster dose.
